Interim Effects of Zoledronate, Denosumab, or Teriparatide on Bone Microarchitecture in Type 2 Diabetes: A Pilot Trial

What Was Tested

The paper reports a study of Teriparatide, published as a randomized controlled trial.

The researchers aimed to evaluate interim effects of zoledronate, denosumab, or teriparatide on bone microarchitecture in postmenopausal women with T2D at high fracture risk.

Who Took Part

According to the abstract, 129 women were involved.

PubMed indexes the participants as middle-aged adults and older adults, women only.

Participants included 129 postmenopausal women with T2D for more than 5 years and high fracture risk (prior fragility fracture and/or T-score < -2.5 [corrected for T2D] with elevated FRAX®).

How the Study Was Run

In design terms this was a randomized, open-label and pilot study.

The women were allocated by chance, so the Teriparatide group and the comparison group should start out alike.

Being open-label, the Teriparatide study did not mask who received what.

It is described as a pilot, a small early test of whether a larger Teriparatide study would be practical.

A 72-week, randomized, open-label, blinded-end point (PROBE) pilot clinical trial (CTRI/2022/02/039978) was conducted at a single tertiary care center in India.

The outcome measure included a prespecified 24-week interim exploratory analysis focusing on changes in bone microarchitecture assessed by second-generation high-resolution peripheral quantitative computed tomography (HR-pQCT) at the distal tibia and radius.

Bone turnover markers (BTMs) were also evaluated.

What Was Measured

Topics PubMed links to this paper include Zoledronic Acid, Denosumab, Pilot Projects, Teriparatide, Diabetes Mellitus, Type 2, Bone Density Conservation Agents and Bone Density.

Author keywords: HR-pQCT, T2D, diabetic bone disease and zoledronate.

What This Means in Plain Language

The paper is a randomized, open-label and pilot study of Teriparatide in 129 women.

Its findings take up roughly 8 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2026 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: the Teriparatide compound page, all human trials.